Schlegel U - Search Results

1

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: schlegel u. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.

2

Vascular endothelial growth factor (VEGF) in astrocytic gliomas--a prognostic factor?

Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, Schlegel U. Oehring RD, et al. Among authors: schlegel u. J Neurooncol. 1999;45(2):117-25. doi: 10.1023/a:1006333005563. J Neurooncol. 1999. PMID: 10778727

3

Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.

Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U. Kraus JA, et al. Among authors: schlegel u. J Neurooncol. 2000 Jun;48(2):89-94. doi: 10.1023/a:1006402614838. J Neurooncol. 2000. PMID: 11083071

4

Molecular genetic alterations in glioblastomas with oligodendroglial component.

Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel U. Kraus JA, et al. Among authors: schlegel u. Acta Neuropathol. 2001 Apr;101(4):311-20. doi: 10.1007/s004010000258. Acta Neuropathol. 2001. PMID: 11355302

5

Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene.

Kraus JA, Oster C, Sörensen N, Berthold F, Schlegel U, Tonn JC, Wiestler OD, Pietsch T. Kraus JA, et al. Among authors: schlegel u. Neuropathol Appl Neurobiol. 2002 Apr;28(2):136-41. doi: 10.1046/j.1365-2990.2002.00388.x. Neuropathol Appl Neurobiol. 2002. PMID: 11972800

6

Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.

Kristof RA, Neuloh G, Hans V, Deckert M, Urbach H, Schlegel U, Simon M, Schramm J. Kristof RA, et al. Among authors: schlegel u. J Neurooncol. 2002 Sep;59(3):231-7. doi: 10.1023/a:1019987116596. J Neurooncol. 2002. PMID: 12241120

7

Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma.

Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T, Schmidt-Wolf I, Schlegel U. Fliessbach K, et al. Among authors: schlegel u. Arch Neurol. 2003 Apr;60(4):563-8. doi: 10.1001/archneur.60.4.563. Arch Neurol. 2003. PMID: 12707070

8

Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.

Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Schaller C, Deckert M, Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U. Pels H, et al. Among authors: schlegel u. J Clin Oncol. 2003 Dec 15;21(24):4489-95. doi: 10.1200/JCO.2003.04.056. Epub 2003 Nov 3. J Clin Oncol. 2003. PMID: 14597744 Clinical Trial.

9

Meeting report: primary central nervous system lymphoma: standards of care and future perspectives.

Herrlinger U, Korfel A, Hebart H, Schlegel U, Plasswilm L, Illerhaus G, Finke J, Krüger W, Montemurro M, Wolf T, Thiel E, Bamberg M, Weller M, Kanz L; Centers for Neuro-Oncology and Lymphoma, University of Tubingen, Germany. Herrlinger U, et al. Among authors: schlegel u. Onkologie. 2005 Feb;28(2):109-11. doi: 10.1159/000083374. Epub 2005 Feb 3. Onkologie. 2005. PMID: 15692223

10

[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Kowalski T, Maier C, Reinacher-Schick A, Schlegel U. Kowalski T, et al. Among authors: schlegel u. Schmerz. 2008 Feb;22(1):16-23. doi: 10.1007/s00482-007-0552-5. Schmerz. 2008. PMID: 17578604 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

306 results

Search Page